35 articles
Steroid-induced osteoporosis
Steroid-induced osteoporosis, or glucocorticoid-induced osteoporosis (GIOP), is iatrogenic bone loss from steroid therapy, the most common secondary osteoporosis, causing rapid dose-dependent fracture risk and treated with bisphosphonates or teriparatide.
STOPP-CIS study
STOPP-CIS (NCT01663129), a Canadian 6-year observational cohort led by Leanne Ward at CHEO, followed 406 children starting glucocorticoids for leukemia, rheumatic disease, or nephrotic syndrome, defining pediatric steroid osteoporosis.
Vertebral compression fracture
Vertebral compression fracture (VCF): collapse of a vertebral body, usually from osteoporosis; 1.4 million cases yearly worldwide. Treated first conservatively, with vertebroplasty or kyphoplasty considered after 4–10 weeks if pain persists.
X-linked osteoporosis with fractures
X-linked osteoporosis with fractures (ORPHA 391330, OMIM 300910) is a rare PLS3-related childhood-onset bone dysplasia with recurrent long-bone and vertebral compression fractures, low BMD, and height loss, mainly affecting males.
Zoledronic acid
Zoledronic acid (zoledronate; Reclast/Aclasta, Zometa) is a nitrogen-containing bisphosphonate given intravenously, 5 mg yearly for osteoporosis and Paget's disease and 4 mg monthly for skeletal complications of malignancy, reducing hip, vertebral, and nonvertebral fractures.